Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Association between Low Testosterone Levels and Sarcopenia in Cirrhosis: A Cross-sectional Study.

Moctezuma-Velázquez C, Low G, Mourtzakis M, Ma M, Burak KW, Tandon P, Montano-Loza AJ.

Ann Hepatol. 2018 July - August ,;17(4):615-623. doi: 10.5604/01.3001.0012.0930.

2.

The management of chronic hepatitis C: 2018 guideline update from the Canadian Association for the Study of the Liver.

Shah H, Bilodeau M, Burak KW, Cooper C, Klein M, Ramji A, Smyth D, Feld JJ; Canadian Association for the Study of the Liver.

CMAJ. 2018 Jun 4;190(22):E677-E687. doi: 10.1503/cmaj.170453. No abstract available.

3.

Sofosbuvir-Based Therapy in the Pre-Liver Transplant Setting: The Canadian National Experience.

Al-Judaibi B, Thomas B, Wong P, Benmassaoud A, Chen JH, Dokus MK, Hussaini T, Bilodeau M, Burak KW, Marotta P, Yoshida EM.

Ann Hepatol. 2018 May-June;17(3):437-443. doi: 10.5604/01.3001.0011.7388. Epub 2018 Apr 9.

4.

Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers.

O'Neil CR, Congly SE, Rose MS, Lee SS, Borman MA, Charlton CL, Osiowy C, Swain MG, Burak KW, Coffin CS.

Ann Hepatol. 2018 Mar 1;17(2):232-241. doi: 10.5604/01.3001.0010.8640.

5.

Deep sequencing shows low-level oncogenic hepatitis B virus variants persists post-liver transplant despite potent anti-HBV prophylaxis.

Lau KCK, Osiowy C, Giles E, Lusina B, van Marle G, Burak KW, Coffin CS.

J Viral Hepat. 2018 Jun;25(6):724-732. doi: 10.1111/jvh.12860. Epub 2018 Feb 6.

PMID:
29316067
6.

Real-world treatment of hepatitis C with second-generation direct-acting antivirals: initial results from a multicentre Canadian retrospective cohort of diverse patients.

Aspinall AI, Shaheen AA, Kochaksaraei GS, Haslam B, Lee SS, Macphail G, Kapler J, Larios OE, Burak KW, Swain MG, Borman MA, Coffin CS.

CMAJ Open. 2018 Jan 5;6(1):E12-E18. doi: 10.9778/cmajo.20170059.

7.

The application of reward learning in the real world: Changes in the reward positivity amplitude reflect learning in a medical education context.

Williams CC, Hecker KG, Paget MK, Coderre SP, Burak KW, Wright B, Krigolson OE.

Int J Psychophysiol. 2018 Oct;132(Pt B):236-242. doi: 10.1016/j.ijpsycho.2017.10.010. Epub 2017 Oct 27.

PMID:
29111454
8.

Letter: lipid-lowering effect of tenofovir disoproxil fumarate in chronic hepatitis B-more evidence is needed. Authors' reply.

Shaheen AA, Al-Mattooq M, Yazdanfar S, Burak KW, Swain MG, Congly SE, Borman MA, Lee SS, Myers RP, Coffin CS.

Aliment Pharmacol Ther. 2017 Oct;46(8):770-771. doi: 10.1111/apt.14282. No abstract available.

PMID:
28901569
9.

Tenofovir disoproxil fumarate significantly decreases serum lipoprotein levels compared with entecavir nucleos(t)ide analogue therapy in chronic hepatitis B carriers.

Shaheen AA, AlMattooq M, Yazdanfar S, Burak KW, Swain MG, Congly SE, Borman MA, Lee SS, Myers RP, Coffin CS.

Aliment Pharmacol Ther. 2017 Sep;46(6):599-604. doi: 10.1111/apt.14218. Epub 2017 Jul 13.

PMID:
28707319
10.

Hepatitis B virus testing and linkage to care in a Canadian urban tertiary referral centre: a retrospective cohort study.

Lau KCK, Shaheen AA, Aspinall AA, Ricento Ba T, Qureshi Mba K, Congly SE, Borman MA, Jayakumar S, Eksteen B, Lee SS, Stinton L, Swain MG, Burak KW, Coffin CS.

CMAJ Open. 2017 Jun 6;5(2):E431-E436. doi: 10.9778/cmajo.20170002.

11.

Integration of Contrast-enhanced US into a Multimodality Approach to Imaging of Nodules in a Cirrhotic Liver: How I Do It.

Jo PC, Jang HJ, Burns PN, Burak KW, Kim TK, Wilson SR.

Radiology. 2017 Feb;282(2):317-331. doi: 10.1148/radiol.2016151732. Review.

PMID:
28099108
12.

A Rapid Bedside Screen to Predict Unplanned Hospitalization and Death in Outpatients With Cirrhosis: A Prospective Evaluation of the Clinical Frailty Scale.

Tandon P, Tangri N, Thomas L, Zenith L, Shaikh T, Carbonneau M, Ma M, Bailey RJ, Jayakumar S, Burak KW, Abraldes JG, Brisebois A, Ferguson T, Majumdar SR.

Am J Gastroenterol. 2016 Dec;111(12):1759-1767. doi: 10.1038/ajg.2016.303. Epub 2016 Aug 2.

PMID:
27481305
13.

Validation of the Model of End-Stage Liver Disease for Liver Transplant Allocation in Alberta: Implications for Future Directions in Canada.

Burak KW, Meeberg GA, Myers RP, Fick GH, Swain MG, Bain VG, Kneteman NM, Hilsden RJ.

Can J Gastroenterol Hepatol. 2016;2016:1329532. doi: 10.1155/2016/1329532. Epub 2016 Apr 3.

14.

STAT order: Should patients with chronic liver disease be prescribed statins to prevent fibrosis progression and hepatocellular carcinoma?

Abraldes JG, Burak KW.

Hepatology. 2016 Jul;64(1):13-5. doi: 10.1002/hep.28537. Epub 2016 Apr 15. No abstract available.

PMID:
26946464
15.

Treatment outcomes with telaprevir-based therapy for HIV/hepatitis C coinfected patients are comparable with hepatitis C monoinfected patients.

O'Neil CR, Pang JX, Lee SS, Swain MG, Burak KW, Klein P, Myers RP, Kapler J, Gill MJ, Labrie M, Coffin CS.

Can J Infect Dis Med Microbiol. 2015 Nov-Dec;26(6):293-6. No abstract available.

16.

Validation of coding algorithms for the identification of patients hospitalized for alcoholic hepatitis using administrative data.

Pang JX, Ross E, Borman MA, Zimmer S, Kaplan GG, Heitman SJ, Swain MG, Burak KW, Quan H, Myers RP.

BMC Gastroenterol. 2015 Sep 11;15:116. doi: 10.1186/s12876-015-0348-5.

17.

Making progress in the ethical treatment of medical trainees.

Busche K, Burak KW, Veale P, Coderre S, McLaughlin K.

Adv Health Sci Educ Theory Pract. 2016 Aug;21(3):711-8. doi: 10.1007/s10459-015-9617-x. Epub 2015 Jun 20.

PMID:
26092833
18.

Validation, current use and future directions of the Model for End-stage Liver Disease for liver transplant allocation in Canada.

Burak KW, Meeberg GA, Myers RP, Fick GH, Swain MG, Bain VG, Kneteman NM, Hilsden RJ.

Can J Gastroenterol Hepatol. 2015 Jun 15. pii: 16942. [Epub ahead of print] No abstract available.

PMID:
26076400
21.

An update on the management of chronic hepatitis C: 2015 Consensus guidelines from the Canadian Association for the Study of the Liver.

Myers RP, Shah H, Burak KW, Cooper C, Feld JJ.

Can J Gastroenterol Hepatol. 2015 Jan-Feb;29(1):19-34. Epub 2015 Jan 13. Erratum in: Can J Gastroenterol Hepatol. 2015 Mar;29(2):68.

22.

A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma.

McNamara MG, Le LW, Horgan AM, Aspinall A, Burak KW, Dhani N, Chen E, Sinaei M, Lo G, Kim TK, Rogalla P, Bathe OF, Knox JJ.

Cancer. 2015 May 15;121(10):1620-7. doi: 10.1002/cncr.29227. Epub 2015 Jan 6.

23.

The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long-term nucleos(t)ide analogue therapy.

Coffin CS, Rezaeeaval M, Pang JX, Alcantara L, Klein P, Burak KW, Myers RP.

Aliment Pharmacol Ther. 2014 Dec;40(11-12):1262-9. doi: 10.1111/apt.12990. Epub 2014 Oct 13.

24.

Protease inhibitor-based triple therapy is highly effective for hepatitis C recurrence after liver transplant: a multicenter experience.

Faisal N, Yoshida EM, Bilodeau M, Wong P, Ma M, Burak KW, Al-Judaibi B, Renner EL, Lilly LB.

Ann Hepatol. 2014 Sep-Oct;13(5):525-32.

25.

Validation of the five-variable Model for End-stage Liver Disease (5vMELD) for prediction of mortality on the liver transplant waiting list.

Myers RP, Tandon P, Ney M, Meeberg G, Faris P, Shaheen AA, Aspinall AI, Burak KW.

Liver Int. 2014 Sep;34(8):1176-83. doi: 10.1111/liv.12373. Epub 2013 Nov 20.

PMID:
24256642
26.

Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy.

Burak KW, Swain MG, Santodomingo-Garzon T, Lee SS, Urbanski SJ, Aspinall AI, Coffin CS, Myers RP.

Can J Gastroenterol. 2013;27(5):273-80. Erratum in: Can J Gastroenterol. 2013 Jun;27(6):376. Santodomino-Garzon, Tania [corrected to Santodomingo-Garzon, Tania].

27.

B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.

Myers RP, Swain MG, Lee SS, Shaheen AA, Burak KW.

Am J Gastroenterol. 2013 Jun;108(6):933-41. doi: 10.1038/ajg.2013.51. Epub 2013 May 7.

PMID:
23649186
28.

Revision of MELD to include serum albumin improves prediction of mortality on the liver transplant waiting list.

Myers RP, Shaheen AA, Faris P, Aspinall AI, Burak KW.

PLoS One. 2013;8(1):e51926. doi: 10.1371/journal.pone.0051926. Epub 2013 Jan 18.

29.

Cardiac work-up protocol for liver transplant candidates: experience from a single liver transplant centre.

Ye C, Saincher M, Tandon P, Meeberg G, Williams R, Burak KW, Bain VG.

Can J Gastroenterol. 2012 Nov;26(11):806-10.

30.

Phenytoin-induced reduction in sirolimus levels.

Bates D, Burak KW, Coffin CS, Ying T, Enns EM.

Can J Hosp Pharm. 2011 Jul;64(4):271-4. No abstract available.

32.

Hepatitis B immunoglobulin for prevention of hepatitis B virus infection and recurrence after liver transplantation.

Congly SE, Burak KW, Coffin CS.

Expert Rev Clin Immunol. 2011 Jul;7(4):429-36. doi: 10.1586/eci.11.30. Review.

PMID:
21790285
33.

Is surgical resection still the treatment of choice for early hepatocellular carcinoma?

Burak KW, Bathe OF.

J Surg Oncol. 2011 Jul 1;104(1):1-2. doi: 10.1002/jso.21765. No abstract available.

PMID:
21656522
34.

Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?

Burak KW.

Oncology (Williston Park). 2011 Mar;25(3):296, 298, 300. Review. No abstract available.

PMID:
21548474
35.

Hepatitis B awareness and education: a failing grade.

Burak KW, Coffin CS, Myers RP.

Can J Gastroenterol. 2011 Mar;25(3):125-6. No abstract available.

36.
37.

Gender, renal function, and outcomes on the liver transplant waiting list: assessment of revised MELD including estimated glomerular filtration rate.

Myers RP, Shaheen AA, Aspinall AI, Quinn RR, Burak KW.

J Hepatol. 2011 Mar;54(3):462-70. doi: 10.1016/j.jhep.2010.07.015. Epub 2010 Sep 19.

PMID:
21109324
38.

Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.

Burak KW, Thomas MB, Zhu AX.

HPB (Oxford). 2010 Jun;12(5):321-2. doi: 10.1111/j.1477-2574.2010.00186.x. No abstract available.

39.

Pregnancy outcomes among liver transplant recipients in the United States: a nationwide case-control analysis.

Coffin CS, Shaheen AA, Burak KW, Myers RP.

Liver Transpl. 2010 Jan;16(1):56-63. doi: 10.1002/lt.21906.

40.

Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: a population-based study.

Myers RP, Shaheen AA, Fong A, Burak KW, Wan A, Swain MG, Hilsden RJ, Sutherland L, Quan H.

Hepatology. 2009 Dec;50(6):1884-92. doi: 10.1002/hep.23210.

PMID:
19821525
41.

Prediction of cardiac complications after liver transplantation.

Fouad TR, Abdel-Razek WM, Burak KW, Bain VG, Lee SS.

Transplantation. 2009 Mar 15;87(5):763-70. doi: 10.1097/TP.0b013e318198d734.

PMID:
19295324
42.

Population-based review of the outcomes following hepatic resection in a Canadian health region.

Dixon E, Bathe OF, McKay A, You I, Dowden S, Sadler D, Burak KW, McKinnon JG, Miller W, Sutherland FR.

Can J Surg. 2009 Feb;52(1):12-7.

43.

Survival after liver transplantation for hepatitis C is unchanged over two decades in Canada.

Watt KD, Burak KW, Deschênes M, Lilly L, Marleau D, Marotta P, Mason A, Peltekian KM, Renner E, Yoshida EM; Canadian Transplant Hepatology Outcomes Research Network.

Can J Gastroenterol. 2008 Feb;22(2):153-4.

44.

The risk of microscopic colitis in solid-organ transplantation patients: a population-based study.

Kaplan GG, Seminowich S, Williams J, Muruve D, Dupre M, Urbanski SJ, Yilmaz S, Burak KW, Beck PL.

Transplantation. 2008 Jan 15;85(1):48-54. doi: 10.1097/01.tp.0000298001.66377.a2.

PMID:
18192911
45.

Population-based analysis of practices and costs of surveillance for colonic dysplasia in patients with primary sclerosing cholangitis and colitis.

Kaplan GG, Heitman SJ, Hilsden RJ, Urbanski S, Myers RP, Lee SS, Burak KW, Swain M, Panaccione R.

Inflamm Bowel Dis. 2007 Nov;13(11):1401-7.

PMID:
17600816
46.

The impact of pathologist experience on liver transplant biopsy interpretation.

Coffin CS, Burak KW, Hart J, Gao ZH.

Mod Pathol. 2006 Jun;19(6):832-8.

47.

Lamivudine for the treatment of membranous glomerulopathy secondary to chronic Hepatitis B infection.

Gan SI, Devlin SM, Scott-Douglas NW, Burak KW.

Can J Gastroenterol. 2005 Oct;19(10):625-9. Review.

PMID:
16247526
49.

A randomized, controlled crossover trial of ondansetron in patients with primary biliary cirrhosis and fatigue.

Theal JJ, Toosi MN, Girlan L, Heslegrave RJ, Huet PM, Burak KW, Swain M, Tomlinson GA, Heathcote EJ.

Hepatology. 2005 Jun;41(6):1305-12.

PMID:
15915460
50.

Are you willing to implicate villin in progressive cholestasis of childhood?

Burak KW.

Can J Gastroenterol. 2005 Apr;19(4):261; discussion 262. No abstract available.

PMID:
15861271

Supplemental Content

Loading ...
Support Center